Metabolites in Safety Testing (MIST): Considerations of Mechanisms of Toxicity with Dose, Abundance, and Duration of Treatment

被引:103
|
作者
Smith, Dennis A. [1 ]
Obach, R. Scott [2 ]
机构
[1] Pfizer Inc, Pharmacokinet Dynam & Metab, Sandwich, Kent, England
[2] Pfizer Inc, Dynam & Metab, Groton, CT 06340 USA
关键词
HUMAN LIVER-MICROSOMES; HUMAN UDP-GLUCURONOSYLTRANSFERASES; AMMONIUM-LINKED GLUCURONIDATION; RECEPTOR ANTAGONIST CP-122,721; ALDEHYDE OXIDASE ACTIVITY; IN-VITRO; SPECIES-DIFFERENCES; N-GLUCURONIDATION; DRUG-METABOLISM; PARTIAL AGONIST;
D O I
10.1021/tx800415j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In previous papers, we have offered a strategic framework regarding metabolites of drugs in humans and the need to assess these in laboratory animal species (also termed Metabolites in Safety Testing or MIST; Smith and Obach, Chem. Res. Toxicol. (2006) 19, 1570-1579). Three main tenets of this framework were founded in (i) comparisons of absolute exposures (as circulating concentrations or total body burden), (ii) the nature of the toxicity mechanism (i.e., reversible interaction at specific targets versus covalent binding to multiple macromolecules), and (iii) the biological matrix in which the metabolite was observed (circulatory vs excretory). In the present review, this framework is expanded to include a fourth tenet: considerations for the duration of exposure. Basic concepts of pharmacology are utilized to rationalize the relationship between exposure (to parent drug or metabolite) and various effects ranging from desired therapeutic effects through to severe toxicities. Practical considerations of human ADME (absorption-distribution-metabolism-excretion) data, to determine which metabolites should be further evaluated for safety, are discussed. An analysis of recently published human ADME studies shows that the number of drug metabolites considered to be important for MIST can be excessively high if a simple percentage-of-parent-drug criterion is used without consideration of the aforementioned four tenets. Concern over unique human metabolites has diminished over the years as experience has shown that metabolites of drugs in humans will almost always be observed in laboratory animals, although the proportions may vary. Even if a metabolite represents a high proportion of the dose in humans and a low proportion in animals, absolute abundances in animals frequently exceed that in humans because the doses used in animal toxicology studies are much greater than therapeutic doses in humans. The review also updates the enzymatic basis for the differences between species and how these relate to MIST considerations.
引用
收藏
页码:267 / 279
页数:13
相关论文
共 31 条
  • [21] High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions
    Marabondo, Stephen
    Kaufman, Howard L.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (12) : 1347 - 1357
  • [22] INTERIM EVALUATION OF THE EFFICACY AND SAFETY OF A HIGH DOSE SHORT DURATION ENROFLOXACIN TREATMENT REGIMEN FOR URINARY TRACT INFECTION IN DOGS.
    Irom, S.
    Westropp, J.
    Chew, D.
    Daniels, J.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2011, 25 (03) : 723 - 723
  • [23] SURVIVAL BENEFIT OF VITAMIN C FOR SHORT-TERM MORTALITY IS DEPENDENT ON CONTROL-GROUP MORTALITY, DOSE, AND DURATION OF TREATMENT: PRESUMED TOXICITY DUE TO TRUNCATED TREATMENT?
    Black, Daniel
    Black, Liliana
    CHEST, 2023, 164 (04) : 1558A - 1558A
  • [24] Hot and cold executive functions in pure opioid users undergoing methadone maintenance treatment: Effects of methadone dose, treatment duration, and time between last methadone administration and testing
    Barahmand, U.
    Tavakolian, E.
    Khazaee, A.
    Mohammadi, K.
    NIGERIAN JOURNAL OF CLINICAL PRACTICE, 2016, 19 (05) : 603 - 610
  • [25] Safety of [177Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity
    Eline A. M. Ruigrok
    Marjolein Verhoeven
    Mark W. Konijnenberg
    Erik de Blois
    Corrina M. A. de Ridder
    Debra C. Stuurman
    Luisa Bertarione
    Katia Rolfo
    Marion de Jong
    Simone U. Dalm
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 4440 - 4451
  • [26] Safety of [177Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity
    Ruigrok, Eline A. M.
    Verhoeven, Marjolein
    Konijnenberg, Mark W.
    de Blois, Erik
    de Ridder, Corrina M. A.
    Stuurman, Debra C.
    Bertarione, Luisa
    Rolfo, Katia
    de Jong, Marion
    Dalm, Simone U.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (13) : 4440 - 4451
  • [27] Safety of dual antiplatelet therapy using aspirin and low-dose Prasugrel with platelet reactivity testing in flow diverter treatment of intracranial aneurysms
    Flynn, Liam M.
    Mohamed, Ezaz
    Dobbs, Nicholas
    Nania, Alberto
    Du Plessis, Johannes
    Keston, Peter M.
    Downer, Jonny J.
    INTERVENTIONAL NEURORADIOLOGY, 2023,
  • [28] Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia: a protocol for a randomIsed controlled Trial (CAP-IT)
    Lyttle, Mark D.
    Bielicki, Julia A.
    Barratt, Sam
    Dunn, David
    Finn, Adam
    Harper, Lynda
    Jackson, Pauline
    Powell, Colin V. E.
    Roland, Damian
    Stohr, Wolfgang
    Sturgeon, Kate
    Wan, Mandy
    Little, Paul
    Faust, Saul N.
    Robotham, Julie
    Hay, Alastair D.
    Gibb, Diana M.
    Sharland, Mike
    BMJ OPEN, 2019, 9 (05):
  • [29] Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial
    Cochereau, Isabelle
    Goldschmidt, Pablo
    Goepogui, Andre
    Afghani, Tayyab
    Delval, Laurent
    Pouliguen, Pascale
    Bourcier, Tristan
    Robert, Pierre-Yves
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2007, 91 (05) : 667 - 672
  • [30] SINGLE-DOSE STUDY COMPARING THE SAFETY EFFICACY, AND DURATION OF EFFECT OF NAPROXEN SODIUM (NS), EXTRA-STRENGTH TYLENOL (EST) AND PLACEBO (P) IN THE TREATMENT OF PAIN SECONDARY TO DENTAL IMPACTION SURGERY
    KIERSCH, T
    HALLADAY, S
    AUSTIN, J
    MILLER, V
    BASSETT, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (02) : 166 - 166